Current perspectives of bispecific antibody-based immunotherapy

R. Talac, H. Nelson

Research output: Contribution to journalReview article

12 Scopus citations


The field of bispecific antibodies is an evolving field of research that has increasing clinical appeal. The fusion of two antibodies or antibody fragments introduced a new way to override natural specificity of T cell and induce effector responses against tumor targets in MHC-unrestricted manner. Initial experiences with bispecific antibodies demonstrate both the promise for and limitations of this anti-cancer strategy. Significant body of work has shown that bispecific antibodies have potential to induce T cell mediated anti-tumor responses in pre-clinical models. However, Immunotherapy with bispecific antibodies in humans has yet to prove its value in clinical settings. In addition, the production of high-quality bispecific antibodies for clinical applications, the optimal size and avidity of bispecific antibodies, and in vivo T cell pre-activation remain critical issues. In this review, we summarize recent progress in bispecific antibody-based immunotherapy and address essential aspects of this anti-cancer strategy.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalJournal of biological regulators and homeostatic agents
Issue number3
StatePublished - Jan 1 2001


  • Bispecific antibodies
  • Cancer
  • Immunotherapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Physiology
  • Immunology
  • Oncology
  • Endocrinology
  • Physiology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'Current perspectives of bispecific antibody-based immunotherapy'. Together they form a unique fingerprint.

  • Cite this